Neuphoria Therapeutics Inc.
(NASDAQ: NEUP)
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
8.500
+0.100
(+1.19%)
Range
8.450 - 8.732
(3.34%)
Open
8.560
Previous Close
8.400
Bid Price
-
Bid Volume
-
Ask Price
-
Ask Volume
-
Volume
39,858
Value
-
Remark
View All Events
No Post Available
Please login to view stock data and analysis